-
Innovent and Incyte Announce Strategic Collaboration and Licensing Agreement for Three Clinical-stage Product Candidates in China
pharmafocusasia
December 17, 2018
Innovent Biologics, Inc. and Incyte today announced that the companies, through their respective subsidiaries, have entered into a strategic collaboration agreement for .....
-
Rodin Therapeutics Announces Initiation of Phase 1 Clinical Trial of a Selective CoREST Inhibitor to Treat Neurologic Diseases
pharmafocusasia
December 13, 2018
Rodin Therapeutics today announced the initiation of a Phase 1 clinical trial of the company’s lead candidate, RDN-929, a potent and selective HDAC-CoREST inhibitor.
-
GlaxoSmithKline to buy Tesaro for $5.1 billion, gaining PARP inhibitor Zejula
firstwordpharma
December 03, 2018
GlaxoSmithKline announced Monday an agreement to acquire Tesaro for around $5.1 billion in cash, gaining the latter's oral PARP inhibitor Zejula (niraparib). GlaxoSmithKline CEO Emma Walmsley said the deal "will strengthen our pharmaceuticals business by
-
CStone’s MEK inhibitor approved for trials in China
pharmaceutical-technology
August 01, 2018
CStone Pharmaceuticals has announced its CS3006, a small molecule inhibitor of mitogen-activated protein kinase (MEK), has received investigational new drug approval for clinical trials from the China National Drug Administration (CNDA). This comes only t
-
Bristol-Myers posts early checkpoint combination data on fast-advancing rival to Incyte’s IDO1 inhib
fiercebiotech
November 13, 2017
Bristol-Myers Squibb has posted interim data on its IDO1 inhibitor in combination with Opdivo.
-
Daiichi Sankyo Enters Worldwide Licensing Agreement with Boston Pharmaceuticals
americanpharmaceuticalreview
August 30, 2017
Daiichi Sankyo and Boston Pharmaceuticals have entered into a worldwide licensing agreement for Daiichi Sankyo's novel RET inhibitor, DS-5010.
ALL
Pharma?in?China
Pharma?Experts
Market News
Products Guide
Brand Story
Pharma Sources Insight July 2025
